PI3K and cancer: lessons, challenges and opportunities (original) (raw)

• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Beagle, B. & Fruman, D. A. A lipid kinase cousin cooperates to promote cancer. Cancer Cell 19, 693–695 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Soler, A. et al. Inhibition of the p110α isoform of PI3-kinase stimulates nonfunctional tumor angiogenesis. J. Exp. Med. 210, 1937–1945 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A. & Martini, M. PI3K in cancer–stroma interactions: bad in seed and ugly in soil. Oncogene http://dx.doi.org/10.1038/onc.2013.265 (2013).
• Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535–602 (2001).
  Article CAS PubMed Google Scholar
• Zhao, J. J. & Roberts, T. M. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci. STKE 2006, e52 (2006).
  Article Google Scholar
• Lemmon, M. A. Membrane recognition by phospholipid-binding domains. Nature Rev. Mol. Cell Biol. 9, 99–111 (2008).
  Article CAS Google Scholar
• Samuels, Y. & Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77–82 (2006).
  Article CAS PubMed Google Scholar
• Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nature Rev. Mol. Cell Biol. 13, 283–296 (2012).
  Article CAS Google Scholar
• Lui, V. W. et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3, 761–769 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550–562 (2009).
  Article CAS Google Scholar
• Berndt, A. et al. The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nature Chem. Biol. 6, 244 (2010).
  Article CAS Google Scholar
• Huang, C. H. et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kα mutations. Science 318, 1744–1748 (2007).
  Article CAS PubMed Google Scholar
• Miled, N. et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239–242 (2007). References 13 and 14 are two hallmark structural studies of p110α.
  Article CAS PubMed Google Scholar
• Vadas, O., Burke, J. E., Zhang, X., Berndt, A. & Williams, R. L. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 4, re2 (2011).
  Article PubMed CAS Google Scholar
• Walker, E. H., Perisic, O., Ried, C., Stephens, L. & Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313–320 (1999). This paper reports first X-ray structure of a class I PI3K.
  Article CAS PubMed Google Scholar
• Wu, H. et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc. Natl Acad. Sci. USA 106, 20258–20263 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, X. et al. Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol. Cell 41, 567–578 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Garcia-Echeverria, C. & Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511–5526 (2008).
  Article CAS PubMed Google Scholar
• Wander, S. A., Hennessy, B. T. & Slingerland, J. M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 121, 1231–1241 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Workman, P., Clarke, P. A., Raynaud, F. I. & van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 70, 2146–2157 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Agarwal, R., Carey, M., Hennessy, B. & Mills, G. B. PI3K pathway-directed therapeutic strategies in cancer. Curr. Opin. Investigat. Drugs 11, 615–628 (2010).
  CAS Google Scholar
• Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784, 159–185 (2008).
  Article CAS PubMed Google Scholar
• Yap, T. A. et al. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393–412 (2008).
  Article CAS PubMed Google Scholar
• Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Rev. Clin. Oncol. 10, 143–153 (2013).
  Article CAS Google Scholar
• Klempner, S. J., Myers, A. P. & Cantley, L. C. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 3, 1345–1354 (2013).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008). This paper provides the first proof of concept in vivo for co-targeting PI3K and MEK.
  Article CAS PubMed Google Scholar
• Ilic, N., Utermark, T., Widlund, H. R. & Roberts, T. M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl Acad. Sci. USA 108, E699–E708 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, P. et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Med. 17, 1116–1120 (2011). This reversible PIK3CA model showed mechanisms of relapse.
  Article CAS PubMed Google Scholar
• Kinross, K. M. et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553–557 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Tikoo, A. et al. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS ONE 7, e36924 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Fruman, D. A. & Rommel, C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1, 562–572 (2011).
  Article CAS PubMed Google Scholar
• Macias-Perez, I. M. & Flinn, I. W. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr. Hematol. Malignancy Rep. 8, 22–27 (2013).
  Article Google Scholar
• Burger, J. A. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24, 643–649 (2012).
  Article CAS PubMed Google Scholar
• Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
  Article CAS PubMed Google Scholar
• Riley, J. L. Combination checkpoint blockade — taking melanoma immunotherapy to the next level. N. Engl. J. Med. 369, 187–189 (2013).
  Article CAS PubMed Google Scholar
• Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403–414 (2008).
  Article CAS PubMed Google Scholar
• Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nature Rev. Mol. Cell Biol. 11, 329–341 (2010).
  Article CAS Google Scholar
• Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050–1063 (2013). This paper reports the discovery that RAC and CDC42, and not RAS, contribute to the activation of p110β.
  Article CAS PubMed PubMed Central Google Scholar
• Fruman, D. A. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem. Soc. Trans. 32, 315–319 (2004).
  Article CAS PubMed Google Scholar
• Hawkins, P. T., Stephens, L. R., Suire, S. & Wilson, M. PI3K signaling in neutrophils. Curr. Top. Microbiol. Immunol. 346, 183–202 (2010).
  CAS PubMed Google Scholar
• Okkenhaug, K., Ali, K. & Vanhaesebroeck, B. Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K. Trends Immunol. 28, 80–87 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Okkenhaug, K. & Fruman, D. A. PI3Ks in lymphocyte signaling and development. Curr. Top. Microbiol. Immunol. 346, 57–85 (2011).
  Google Scholar
• Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107, 11381–11386 (2010). This paper provides evidence for the redundant functions of PI3K isoforms in cell proliferation and survival.
  Article CAS PubMed PubMed Central Google Scholar
• Dbouk, H. A. et al. Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase. PLoS ONE 8, e63833 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cheung, L. W. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1, 170–185 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jaiswal, B. S. et al. Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16, 463–474 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, M., Hillmann, P., Hofmann, B. T., Hart, J. R. & Vogt, P. K. Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α. Proc. Natl Acad. Sci. USA 107, 15547–15552 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286–4293 (2009).
  Article CAS PubMed Google Scholar
• Ludovini, V. et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6, 707–715 (2011).
  Article PubMed Google Scholar
• Suda, K., Mizuuchi, H., Maehara, Y. & Mitsudomi, T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation — diversity, ductility, and destiny. Cancer Metastasis Rev. 31, 807–814 (2012).
  Article CAS PubMed Google Scholar
• Cybulski, N. & Hall, M. N. TOR complex 2: a signaling pathway of its own. Trends Biochem. Sci. 34, 620–627 (2009).
  Article CAS PubMed Google Scholar
• Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 144, 757–768 (2011).
  Article CAS PubMed Google Scholar
• Huang, J. & Manning, B. D. The TSC1–TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179–190 (2008).
  Article CAS PubMed Google Scholar
• Dibble, C. C. et al. TBC1D7 is a third subunit of the TSC1–TSC2 complex upstream of mTORC1. Mol. Cell 47, 535–546 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Guertin, D. A. et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148–159 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Nardella, C. et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2, ra2 (2009). References 57 and 58 genetically validate mTOR as a selective cancer target in prostate cancer.
  Article PubMed PubMed Central CAS Google Scholar
• Evangelisti, C. et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25, 781–791 (2011).
  Article CAS PubMed Google Scholar
• Janes, M. R. et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Med. 16, 205–213 (2010).
  Article CAS PubMed Google Scholar
• Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58–71 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rodrik-Outmezguine, V. S. et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1, 248–259 (2011). This is a detailed analysis of the feedback effects of mTOR kinase inhibitors and the role of FOXO transcription factors.
  Article CAS PubMed PubMed Central Google Scholar
• Ballif, B. A. et al. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl Acad. Sci. USA 102, 667–672 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179–193 (2005).
  Article CAS PubMed Google Scholar
• Ma, L. et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 67, 7106–7112 (2007).
  Article CAS PubMed Google Scholar
• Tabernero, J. et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26, 1603–1610 (2008).
  Article CAS PubMed Google Scholar
• She, Q. B. et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39–51 (2010). This paper provides evidence for the convergence of PI3K–AKT and RAS–ERK signals at the level of 4EBPs.
  Article CAS PubMed PubMed Central Google Scholar
• Wang, X. et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell. Biol. 27, 7405–7413 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, T., Yao, G., Nevins, J. & You, L. Sensing and integration of Erk and PI3K signals by Myc. PLoS Computat. Biol. 4, e1000013 (2008).
  Article CAS Google Scholar
• Brachmann, S. M. et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11, 1747–1757 (2012).
  Article CAS PubMed Google Scholar
• Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88–94 (2013).
  Article CAS PubMed Google Scholar
• Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
  Article CAS PubMed Google Scholar
• Garrett, J. T. et al. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 73, 6013–6023 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, S. et al. Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice. Cell 129, 957–968 (2007). This knock-in mouse defined a role for p110α in RAS transformation.
  Article CAS PubMed Google Scholar
• Nacht, M. et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. J. Med. Chem. 56, 712–721 (2013).
  Article CAS PubMed Google Scholar
• Lee, J. H. et al. De novo somatic mutations in components of the PI3K–AKT3–mTOR pathway cause hemimegalencephaly. Nature Genet. 44, 941–945 (2012).
  Article CAS PubMed Google Scholar
• Lindhurst, M. J. et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nature Genet. 44, 928–933 (2012).
  Article CAS PubMed Google Scholar
• Riviere, J. B. et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nature Genet. 44, 934–940 (2012).
  Article CAS PubMed Google Scholar
• Angulo, I. et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nature Immunol. http://dx.doi.org/10.1038/ni.2771 (2013). References 81 and 82 identify human immunodeficiency patients with gain-of-function mutations affecting p110δ.
• Jia, S. et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454, 776–779 (2008). This paper provides the first genetic evidence for p110β function in tumorigenesis.
  Article CAS PubMed PubMed Central Google Scholar
• Torbett, N. E. et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 415, 97–110 (2008).
  Article CAS PubMed Google Scholar
• Wee, S. et al. PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105, 13057–13062 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Berenjeno, I. M. et al. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem. J. 442, 151–159 (2012).
  Article CAS PubMed Google Scholar
• Iyengar, S. et al. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 121, 2274–2284 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, N. et al. BAY 80–6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12, 2319–2330 (2013).
  Article CAS PubMed Google Scholar
• Subramaniam, P. S. et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 21, 459–472 (2012). This paper provides proof of concept for the dual targeting of p110γ and p110δ in T cell leukaemia.
  Article CAS PubMed Google Scholar
• Winkler, D. G. et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364–1374 (2013).
  Article CAS PubMed Google Scholar
• Boyle, D. L. Kim, H. R., Topolewski, K., Bartok, B. & Firestein, G. S. Novel dual phosphoinositide 3-kinase-δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J. Pharmacol. Exp. Ther. http://dx.doi.org/10.1124/jpet.113.205955 (2013).
• Schmid, M. C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715–727 (2011). This study shows that p110γ activity in myeloid cells acts downstream of diverse receptors and promotes the formation of solid tumours even though the isoform is not expressed in cancer cells.
  Article CAS PubMed PubMed Central Google Scholar
• So, L. et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J. Biol. Chem. 288, 5718–5731 (2013).
  Article CAS PubMed Google Scholar
• Brunn, G. J. et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256–5267 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Gharbi, S. I. et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15–21 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kharas, M. G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038–3050 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Elkabets, M. et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5, 196ra99 (2013). This study demonstrates that mTORC1 preserves survival in PIK3CA -mutant cells treated with p110α inhibitors.
  Article PubMed PubMed Central CAS Google Scholar
• Yuan, R., Kay, A., Berg, W. J. & Lebwohl, D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2, 45 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 4, 135–142 (2009).
  Article PubMed Google Scholar
• Benjamin, D., Colombi, M., Moroni, C. & Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Rev. Drug Discov. 10, 868–880 (2011).
  Article CAS Google Scholar
• Janes, M. R. & Fruman, D. A. Targeting TOR dependence in cancer. Oncotarget 1, 69–76 (2010).
  Article PubMed PubMed Central Google Scholar
• Gentzler, R. D., Altman, J. K. & Platanias, L. C. An overview of the mTOR pathway as a target in cancer therapy. Expert Opin. Ther. Targets 16, 481–489 (2012).
  Article CAS PubMed Google Scholar
• Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288–298 (2010).
  Article CAS PubMed Google Scholar
• Yu, K. et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 70, 621–631 (2010).
  Article CAS PubMed Google Scholar
• Garcia-Garcia, C. et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18, 2603–2612 (2012).
  Article CAS PubMed Google Scholar
• Alain, T., Sonenberg, N. & Topisirovic, I. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 3, 1491–1492 (2012).
  Article PubMed PubMed Central Google Scholar
• Martineau, Y. et al. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene http://dx.doi.org/10.1038/onc.2013.100 (2013).
• Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012). This cinical study establishes the combination of rapalogues with anti-oestrogen therapy in breast cancer.
  Article CAS PubMed Google Scholar
• Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Krueger, D. A. et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80, 574–580 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012). This paper demonstrates that genome sequencing of rare responders can identify predictive biomarkers for rapalogue sensitivity.
  Article CAS PubMed PubMed Central Google Scholar
• Bar-Peled, L. et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100–1106 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Panchaud, N., Peli-Gulli, M. P. & De Virgilio, C. Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the Rag family GTPase Gtr1. Sci. Signal. 6, ra42 (2013).
  Article PubMed CAS Google Scholar
• Corcoran, R. B. et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, 196ra98 (2013).
  Article PubMed CAS Google Scholar
• Powell, J. D., Pollizzi, K. N., Heikamp, E. B. & Horton, M. R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39–68 (2012).
  Article CAS PubMed Google Scholar
• Thomson, A. W., Turnquist, H. R. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nature Rev. Immunol. 9, 324–337 (2009).
  Article CAS Google Scholar
• Zeng, H. & Chi, H. mTOR and lymphocyte metabolism. Curr. Opin. Immunol. 25, 347–355 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunol. 12, 295–303 (2011). This is an informative dissection of the functions of mTORC1 and mTORC2 in T cell differentiation, which were determined using genetic and pharmacological approaches.
  Article CAS Google Scholar
• Katholnig, K., Linke, M., Pham, H., Hengstschlager, M. & Weichhart, T. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem. Soc. Trans. 41, 927–933 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Procaccini, C. et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929–941 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zeng, H. et al. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499, 485–490 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 619 (2006).
  Article CAS Google Scholar
• Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
  Article CAS PubMed Google Scholar
• Bellacosa, A., Testa, J. R., Staal, S. P. & Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274–277 (1991).
  Article CAS PubMed Google Scholar
• Rhodes, N. et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366–2374 (2008).
  Article CAS PubMed Google Scholar
• Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688–4695 (2011).
  Article CAS PubMed Google Scholar
• Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728–1731 (2001).
  Article CAS PubMed Google Scholar
• Pal, S. K., Reckamp, K., Yu, H. & Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investigat. Drugs 19, 1355–1366 (2010).
  Article CAS Google Scholar
• Lin, J. et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 19, 1760–1772 (2013).
  Article CAS PubMed Google Scholar
• Vakana, E., Altman, J. K. & Platanias, L. C. Targeting AMPK in the treatment of malignancies. J. Cell. Biochem. 113, 404–409 (2012).
  Article CAS PubMed Google Scholar
• Lindqvist, L. & Pelletier, J. Inhibitors of translation initiation as cancer therapeutics. Future Med. Chem. 1, 1709–1722 (2009).
  Article CAS PubMed Google Scholar
• Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257–267 (2007).
  Article CAS PubMed Google Scholar
• Li, S., Brown, M. S. & Goldstein, J. L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl Acad. Sci. USA 107, 3441–3446 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nature Chem. Biol. 5, 484–493 (2009).
  Article CAS Google Scholar
• Pearce, L. R. et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245–255 (2010).
  Article CAS PubMed Google Scholar
• Tandon, P. et al. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc. Natl Acad. Sci. USA 108, 2361–2365 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Merkel, A. L., Meggers, E. & Ocker, M. PIM1 kinase as a target for cancer therapy. Expert Opin. Investigat. Drugs 21, 425–436 (2012).
  Article CAS Google Scholar
• Yang, J. et al. eIF4B phosphorylation by Pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res. 73, 4898–4908 (2013).
  Article CAS PubMed Google Scholar
• Wendel, H. G. et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232–3237 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638–642 (2013). References 144 and 145 identify promising new approaches to target oncogenic RAS.
  Article CAS PubMed Google Scholar
• Chakrabarty, A. et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 73, 1190–1200 (2013).
  Article CAS PubMed Google Scholar
• Donev, I. S. et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin. Cancer Res. 17, 2260–2269 (2011).
  Article CAS PubMed Google Scholar
• Rexer, B. N. & Arteaga, C. L. Optimal targeting of HER2–PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 73, 3817–3820 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Floris, G. et al. A potent combination of the novel PI3K inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin. Cancer Res. 19, 620–630 (2013).
  Article CAS PubMed Google Scholar
• Young, C. D. et al. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression or signaling. Cancer Res. 73, 4075–4085 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Fiskus, W. et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol. Cancer Ther. 12, 577–588 (2013).
  Article CAS PubMed Google Scholar
• Vogt, P. K. & Hart, J. R. PI3K and STAT3: a new alliance. Cancer Discov. 1, 481–486 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065–3074 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kinkade, C. W. et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118, 3051–3064 (2008).
  CAS PubMed PubMed Central Google Scholar
• Zmajkovicova, K. et al. MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Mol. Cell 50, 43–55 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Posch, C. et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015–4020 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bean, G. R. et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci. Signal. 6, ra20 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Liu, Y. et al. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol. Cancer Ther. 11, 45–56 (2012).
  Article CAS PubMed Google Scholar
• Ellenrieder, V. et al. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61, 4222–4228 (2001).
  CAS PubMed Google Scholar
• Mulholland, D. J. et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72, 1878–1889 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55–61 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Shimizu, T. et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316–2325 (2012).
  Article CAS PubMed Google Scholar
• Coffee, E. M. et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF V600E colorectal cancer. Clin. Cancer Res. 19, 2688–2698 (2013).
  Article CAS PubMed Google Scholar
• Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669–16674 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Dominguez-Sola, D. & Dalla-Favera, R. Burkitt lymphoma: much more than MYC. Cancer Cell 22, 141–142 (2012).
  Article CAS PubMed Google Scholar
• Sander, S. et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22, 167–179 (2012). This paper establishes an animal model for Burkitt's lymphoma, which requires both MYC and active PI3K.
  Article CAS PubMed PubMed Central Google Scholar
• Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116–120 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pourdehnad, M. et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl Acad. Sci. USA 110, 11988–11993 (2013). This paper provides evidence that MYC-driven lymphoma is addicted to mTOR activity.
  Article CAS PubMed PubMed Central Google Scholar
• Grabher, C., von Boehmer, H. & Look, A. T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Rev. Cancer 6, 347–359 (2006).
  Article CAS Google Scholar
• Guo, D., Teng, Q. & Ji, C. NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia. Leuk. Lymphoma 52, 1200–1210 (2011).
  Article CAS PubMed Google Scholar
• Shanware, N. P., Bray, K. & Abraham, R. T. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu. Rev. Pharmacol. Toxicol. 53, 89–106 (2013).
  Article CAS PubMed Google Scholar
• Carayol, N. et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl Acad. Sci. USA 107, 12469–12474 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Fan, Q. W. et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 3, ra81 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kao, G. D., Jiang, Z., Fernandes, A. M., Gupta, A. K. & Maity, A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem. 282, 21206–21212 (2007).
  Article CAS PubMed Google Scholar
• Kumar, A., Fernandez-Capetillo, O. & Carrera, A. C. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc. Natl Acad. Sci. USA 107, 7491–7496 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036–1047 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2, 1048–1063 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bassi, C. et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341, 395–399 (2013). This paper identifies the novel sumoylation and nuclear function of PTEN.
  Article CAS PubMed PubMed Central Google Scholar
• Lempiainen, H. & Halazonetis, T. D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 28, 3067–3073 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Munck, J. M. et al. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol. Cancer Ther. 11, 1789–1798 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Khalaileh, A. et al. Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. Cancer Res. 73, 1811–1820 (2013).
  Article CAS PubMed Google Scholar
• Shen, C. et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks. Cancer Res. 73, 3393–3401 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, F. et al. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia 27, 2040–2046 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452–4461 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS PubMed Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
  Article CAS PubMed Google Scholar
• Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S. & Karin, M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302–305 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Davids, M. S. & Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 30, 3127–3135 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192 (2002).
  Article CAS PubMed Google Scholar
• Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351–365 (2006).
  Article CAS PubMed Google Scholar
• Coloff, J. L. et al. Akt-dependent glucose metabolism promotes mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 71, 5204–5213 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Davids, M. S. et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120, 3501–3509 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rahmani, M. et al. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 73, 1340–1351 (2013).
  Article CAS PubMed Google Scholar
• Hoellenriegel, J. et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603–3612 (2011). This study provides a mechanism for the efficacy of GS-1101 and includes pharmacodynamic data from clinical studies.
  Article CAS PubMed PubMed Central Google Scholar
• Motz, G. T. & Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 39, 61–73 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49–60 (2013).
  Article CAS PubMed Google Scholar
• Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev. Cancer 12, 237–251 (2012).
  Article CAS Google Scholar
• Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74–88 (2013).
  Article CAS PubMed Google Scholar
• Fruman, D. A. & Bismuth, G. Fine tuning the immune response with PI3K. Immunol. Rev. 228, 253–272 (2009).
  Article CAS PubMed Google Scholar
• Okkenhaug, K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31, 675–704 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, Q. et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 71, 4074–4084 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Q. et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 34, 541–553 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Marshall, N. A. et al. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 72, 581–591 (2012). This paper shows that PI3K inhibitors can enhance the adjuvant activity of Toll-like receptor agonists to improve dendritic cell-based tumour vaccines in mice.
  Article CAS PubMed Google Scholar
• Yao, E. et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 15, 4147–4156 (2009).
  Article CAS PubMed Google Scholar
• Mao, M. et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19, 657–667 (2013).
  Article CAS PubMed Google Scholar
• Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750–2760 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Nardella, C., Lunardi, A., Patnaik, A., Cantley, L. C. & Pandolfi, P. P. The APL paradigm and the “co-clinical trial” project. Cancer Discov. 1, 108–116 (2011).
  Article PubMed Google Scholar
• Suire, S. et al. Gβγs and the Ras binding domain of p110γ are both important regulators of PI(3)Kγ signalling in neutrophils. Nature Cell Biol. 8, 1303–1309 (2006).
  Article CAS PubMed Google Scholar
• Delgado, P. et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nature Immunol. 10, 880–888 (2009).
  Article CAS Google Scholar
• Rodriguez-Viciana, P., Sabatier, C. & McCormick, F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24, 4943–4954 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dbouk, H. A. et al. G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci. Signal. 5, ra89 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Durand, C. A. et al. Phosphoinositide 3-kinase p110δ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183, 5673–5684 (2009).
  Article CAS PubMed Google Scholar
• Reif, K. et al. Cutting edge: differential roles for phosphoinositide 3-kinases, 110γ and p110δ, in lymphocyte chemotaxis and homing. J. Immunol. 173, 2236–2240 (2004).
  Article CAS PubMed Google Scholar
• Puri, K. D. & Gold, M. R. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Frontiers Immunol. 3, 256 (2012).
  Article Google Scholar
• Ghosh, B. et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem. Biol. 4, 367–377 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Knauf, U., Tschopp, C. & Gram, H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell. Biol. 21, 5500–5511 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Lim, S. et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc. Natl Acad. Sci. USA 110, E2298–E2307 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Konicek, B. W. et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71, 1849–1857 (2011).
  Article CAS PubMed Google Scholar
• Lin, Y. W. et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115, 824–833 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Blanco-Aparicio, C. et al. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett. 300, 145–153 (2011).
  Article CAS PubMed Google Scholar
• Chen, L. S., Redkar, S., Bearss, D., Wierda, W. G. & Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114, 4150–4157 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Song, J. H. & Kraft, A. S. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 72, 294–303 (2012).
  Article CAS PubMed Google Scholar
• Pogacic, V. et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 67, 6916–6924 (2007).
  Article CAS PubMed Google Scholar
• Rommel, C. et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738–1741 (1999).
  Article CAS PubMed Google Scholar
• Zimmermann, S. & Moelling, K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741–1744 (1999).
  Article CAS PubMed Google Scholar